Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter's Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 Pestle Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Type
6.1 Introduction
6.2 Iodinated Contrast
6.3 Gadolinium-Based Contrast Media
6.4 Microbubble Contrast Media
6.5 Barium-Based Contrast Media
6.6 Y-o-Y Growth Analysis
6.7 Market Attractiveness Analysis
Chapter 7 Global Companion Diagnostics Market, By Strategic Analysis
7.1 Introduction
7.2 Value Chain Analysis
7.3 Pricing Analysis
7.4 Opportunities Analysis
7.5 Others
Chapter 8 Global Companion Diagnostics Market, By Technology
8.1 Introduction
8.2 Polymerase Chain Reaction (PCR)
8.3 Sequencing-based
8.4 In Situ Hybridization
8.5 Immunohistochemistry
Chapter 9 Global Companion Diagnostics Market, By End-Users
9.1 Introduction
9.2 Pharmaceutical Companies
9.3 Reference Laboratories
9.4 cathode-ray oscilloscope(CRO)
9.5 Hospitals
Chapter 10 Global Companion Diagnostics Market, By Indication
10.1 Introduction
10.2 Breast Cancer
10.3 Lung Cancer
10.4 Melanoma
10.5 Gastric Cancer
10.6 Colorectal Cancer
Chapter 11 Market Segmentation, By Geography
11.1 North America
11.1.1 Introduction
11.1.2 United States
11.1.3 Canada
11.1.4 Mexico
11.1.5 Others
11.2 Europe
11.2.1 Introduction
11.2.2 U.K
11.2.3 Spain
11.2.4 Italy
11.2.5 France
11.2.6 Russia
11.2.7 Others
11.3 Asia-Pacific
11.3.1 Introduction
11.3.2 China
11.3.3 India
11.3.4 Japan
11.3.5 Australia
11.3.6 Others
11.4 South America
11.4.1 Introduction
11.4.2 Brazil
11.4.3 Argentina
11.4.4 Others
11.5 The Middle East & Africa
11.5.1 Introduction
11.5.2 Middle-East
11.5.3 Africa
11.5.4 Others
Chapter 12 Competitive Landscape
12.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
12.2 Market Share Analysis
12.3 Strategies Adopted By Top Companies
Chapter 13 Company Profiles
13.1. Abbott Laboratories
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Benchmarking
13.1.4. Strategic Initiative
13.2. Advanced Cell Diagnostics Inc.
13.3. Agilent Technologies, Inc.
13.4. Biomérieux
13.5. Biogenex Laboratories
13.6. Danaher Corporation
13.7. Roche Diagnostics
13.8. Thermo Fisher Scientific, Inc.
13.9. GE Healthcare
13.10. R-Biopharm AG
13.11 Myriad Genetics, Inc.
13.12. Qiagen N.V.
13.13. Cypher Genomics
13.14. Flagship Biosciences
13.15. Applied Proteomics
13.16. Ignyta, Inc.
13.17. Madison Vaccines, Inc.
13.18. Ventana Medical Systems, Inc.
13.19 A&G Pharmaceutical, Inc.
13.20 EKF Diagnostics Holdings plc.
Chapter 14 Market Estimates and Forecast
14.1 Market Estimates and Forecast 2018-2024 (USD Million)
14.1.1 Market Estimation and Forecast by Strategic Analysis 2018-2024 (USD Million)
14.1.2 Market Estimates and Forecast by Technology 2018-2024 (USD Million)
14.1.3 Market Estimates and Forecast by Indication 2018-2024 (USD Million)
14.1.4 Market Estimates and Forecast by End-Users 2018-2024 (USD Million)
14.1.5 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
14.1.6 Market Estimates and Forecast by Company 2018-2024 (USD Million)
Chapter 15 Market Insights
15.1 Insights of Industry Experts
15.2 Analyst Opinion (Market Understanding)
15.3 Investment Opportunities
Chapter 16 Appendix
16.1 List of Tables
16.2 List of Figures
